Imagion Biosystems has updated investors by lodging the latest version of its corporate presentation visuals with the Australian Securities Exchange. Content includes overviews of MagSense® Technology, the medical needs for clinical MagSense imaging, market sizes and growth rates, development milestones, and more.
View the 25 October 2017 Investor Update.
Positive Final Results of Wayne State Collaboration Drives Completion of Phase 2 Study Protocol for IND Submission to FDA in December
December 2, 2025
Positive Final Results of Wayne State Collaboration Drives Completion of Phase 2 Study Protocol for IND Submission to FDA in December Key Highlights: MagSense® HER2